It is very uncertain whether sulphasalazine changes withdrawal due to adverse events compared with placebo (very low certainty).
It is very uncertain whether 5‐ASA changes withdrawal due to adverse events compared with no treatment (very low certainty).
Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide MMX® 9 mg showed no clear difference in withdrawal due to adverse events compared with entocort EC 9mg (moderate certainty).
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).